Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide

Annals of Hematology

Volumn 89, Issue 2, 2010, Pages 201-206

  Koh, Youngil ^a   Bang, Soo Mee ^m   Lee, Jae Hoon ^b   Yoon, Hwi Joong ^c   Do, Young Rok ^d   Ryoo, Hun Mo ^e   Lee, Nari ^f   Kim, Seok Jin ^g   Kim, Kihyun ^g   Yoon, Sung Soo ^a   Won, Jong Ho ^h   Mun, Yeung Chul ⁱ   Lee, Moon Hee ^j   Rhee, Ki Hyun ^k   Kim, Hyo Jung ^l   Eom, HyeonSeok ^m   Kim, Min Kyoung ^m   Shin, Hyun Chun ^m  

^a Seoul National University Hospital   (South Korea)

^b Gachon University College of Medicine   (South Korea)

^c Kyung Hee University Hospital   (South Korea)

^d Dongsan Medical Center   (South Korea)

^e Catholic University of Daegu   (South Korea)

^f Chonbuk National University Medical School   (South Korea)

^g Samsung Medical Center   (South Korea)

^h Soonchunhyang University College of Medicine   (South Korea)

ⁱ Ewha Womans University School of Medicine   (South Korea)

^j Inha University Hospital   (South Korea)

^k Holy Family Hospital   (South Korea)

^l Hallym University Medical Center   (South Korea)

^m NONE

more..

Author keywords

Multiple myeloma; Thalidomide; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; HEPARIN; MELPHALAN; PREDNISOLONE; STEROID; THALIDOMIDE; VINCRISTINE; WARFARIN; ANGIOGENESIS INHIBITOR;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTERY THROMBOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; KOREA; LEG THROMBOSIS; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLIC SYNDROME X; MULTIPLE MYELOMA; OCCLUSIVE CEREBROVASCULAR DISEASE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; FEMALE; HUMANS; INCIDENCE; KOREA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE; THROMBOEMBOLISM;

EID: 74049151212     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0807-6     Document Type: Article

References (35)

1. Lyman GH, Khorana AA, Falanga A et al (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490-5505.
2. Khorana AA, Francis CW, Culakova E et al (2006) Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24:484-490.
3. Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715-722.
4. Heit JA, Silverstein MD, Mohr DN et al (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a populationbased case-control study. Arch Intern Med 160:809-815.
5. Zangari M, Anaissie E, Barlogie B et al (2001) Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98:1614-1615.
6. Shah MA, Ilson D, Kelsen DP (2005) Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 23:2574-2576.
7. Palumbo A, Facon T, Sonneveld P et al (2008) Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111:3968-3977.
8. Singhal S, Mehta J, Desikan R et al (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571.
9. Palumbo A, Giaccone L, Bertola A et al (2001) Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86:399-403.
10. Palumbo A, Avonto I, Bruno B et al (2006) Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Eur J Haematol 76:273-277.
11. Offidani M, Corvatta L, Marconi M et al (2006) Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica 91:133-136.
12. Palumbo A, Rajkumar SV, Dimopoulos MA et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22:414-423.
13. Scarpace SL, Hahn T, Roy H et al (2005) Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma 46:239-242.
14. Weber D, Rankin K, Gavino M et al (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16-19.
15. Zangari M, Barlogie B, Anaissie E et al (2004) Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126:715-721.
16. Minnema MC, Breitkreutz I, Auwerda JJ et al (2004) Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 18:2044-2046.
17. Baz R, Li L, Kottke-Marchant K et al (2005) The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 80:1568-1574.
18. Dispenzieri A, Rajkumar SV, Gertz MA et al (2007) Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 82:323-341.
19. Chew HK, Wun T, Harvey D et al (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166:458-464.
20. Hattori Y, Okamoto S, Shimada N et al (2008) Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma: prognostic factors and unique toxicity profile. Cancer Sci 99:1243-1250.
21. Murakami H, Handa H, Abe M et al (2007) Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. Eur J Haematol 79:234-239.
22. Anagnostopoulos A, Weber D, Rankin K et al (2003) Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121:768-771.
23. Bataille R, Durie BG, Grenier J, Sany J (1986) Prognostic factors and staging in multiple myeloma: a reappraisal. J Clin Oncol 4:80-87.
24. Greipp PR, San Miguel J, Durie BG et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412-3420.
25. Kim JK, Kim YJ, Lee SY (2006) Defining criteria for obesity management using optimal body mass index. Journal of Korean Society for the Study of Obesity 10:10.
26. Ho CH, Chau WK, Hsu HC et al (2000) Causes of venous thrombosis in fifty Chinese patients. Am J Hematol 63:74-78.
27. Shen MC, Lin JS, Tsay W (2000) Protein C and protein S deficiencies are the most important risk factors associated with thrombosis in Chinese venous thrombophilic patients in Taiwan. Thromb Res 99:447-452.
28. Johnson DC, Corthals S, Ramos C et al (2008) Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood 112 (13):4924-4934.
29. White RH, Zhou H, Murin S, Harvey D (2005) Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost 93:298-305.
30. Stein PD, Kayali F, Olson RE, Milford CE (2004) Pulmonary thromboembolism in Asians/Pacific Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census. Am J Med 116:435-442.
31. Kobayashi T, Nakamura M, Sakuma M et al (2006) Incidence of pulmonary thromboembolism (PTE) and new guidelines for PTE prophylaxis in Japan. Clin Hemorheol Microcirc 35:257-259.
32. Mannucci PM (2007) Thrombosis and bleeding disorders outside Western countries. J Thromb Haemost 5(Suppl 1):68-72.
33. Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:381S-453S.
34. Jang MJ, Choi WI, Bang SM, Lee T, Kim YK, Ageno W, Oh D (2009) Metabolic syndrome is associated with venous thromboembolism in the Korean population. Arterioscler Thromb Vasc Biol 29(3):311-315.
35. Verhovsek M, Douketis JD, Yi Q et al (2008) Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 149:481-490 W494.